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1. Introduction  
The growing application of peptides in drug discovery 
necessitates their accurate quantification in order to obtain the 
right metabolic, enzymatic, kinetic and pharmacokinetic data.1-6 
Several methods for peptide quantification have been reported to 
date, these include liquid chromatography combined with 
ultraviolet (UV) or fluorescence detection, capillary 
electrophoresis with UV detection, matrix-assisted laser-
desorption/ionization mass spectrometry (MALDI-MS), surface-
enhanced laser desorption/ionization (SELDI),6-12 liquid 
chromatography- mass spectrometry (LC-MS),7,8 inductively 
coupled plasma mass spectrometry (ICP-MS)13-14 and quantitative 
nuclear magnetic resonance (qNMR).9 
Limitations of these techniques for quantification of peptides 
vary by technique. Matrix effects limit optical techniques such as 
UV and fluorescence detection.7,8 Different mass spectrometric 
methods suffer from different problems. Matrix-assisted laser 
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desorption/ionization–time of flight mass spectrometry (MALDI-
TOF) and electrospray ionisation (ESMS) techniques both suffer 
drawbacks such as differential response of proteins and peptides 
depending on size, hydrophobicity, matrix, or solvents.10 At low 
mass resolution, LC-MS data has a limited accuracy for reported 
intensity of the extracted ion currents due to contamination by 
nearby peptide signals, thereby affecting accurate 
quantification.11,12 For quantification purposes, it is necessary to 
address these issues in particular ionisation efficiency and matrix 
effects when using an ESMS or MALDI-MS direct measurements. 
For this reason various sample treatments for MS-based 
quantification are reported in the literature for peptides including; 
isotope-coded affinity tag reagents (ICATs),13-15 isotope-coded 
protein labelling (ICPL),16-18 stable isotope labelling by amino acid 
in cell culture (SILAC),19-21 isotope-differentiated binding energy 
shift tag (IDBEST), chemical labelling, isobaric tagging (iTRAQ, 
TMT),22,23 and absolute quantification with the use of synthetic 
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labelled peptides (AQUA),24,25 These methods require additional 
sample preparation and cost. 
ICP-MS is a sensitive analytical tool for elemental analysis with 
advantages of having species independence and high ionization 
efficiency for most elements in the periodic table, high sensitivity 
of parts per billion to parts per trillion levels, together with 
affordable isotope distribution information.26-27 For these reasons 
it has become a significant and complementary technique in 
bioanalysis for the determination of biomolecules and 
quantification of therapeutic agents.28-36 Application of ICPMS 
allows the quantification of elements independent of their 
molecular form, hence the analyte retains its original form during 
quantification. Coupled with molecular information obtained from 
ESI-MS or MALDI enables the compound identification 
simultaneously with its quantification. Sulphur has been 
successfully used for the quantification of proteins and peptide in 
biological samples by coupling the ICP-MS to different 
chromatographic systems.37-40 
NMR produces a signal for any species that will have an area 
that is proportional to its concentration.40 Complex mixtures can 
be analyzed by NMR which provides the concentration of the 
chemical components in a mixture, hence allowing quantification 
of species for metabolomic and related studies.41-42 Proton NMR 
quantification (qNMR) by ERETIC is a non-destructive and rapid 
way of providing accurate analyte concentrations43 by using an 
indirect internal reference signal that represents a known 
concentration. This averts the need to determine a compound-
specific response factor,44 making qNMR an accurate and 
straightforward technique for quantification. The drawbacks to 
this method are that it requires relatively pure samples of large size 
that would allow sufficient signal to noise ratio (>150:1)9 and an 
internal certified reference material. 
 Cyclic peptides show promise in many therapeutic areas, 
particularly in complex diseases such as auto-immune disorders.45 
Cyanobactins are a family of modified cyclic peptides that have 
interesting structural features including heterocycles, epimerized 
stereocentres and prenylated residues (Figure 1).46 Some of these 
modifications lead to better target affinity by constraining 
conformational flexibility, while others increase cellular 
permeability.47,48 Members of cyanobactins are known to reverse 
multi drug resistance in human lymphoblasts by inhibiting the P-
glycoprotein (Pgp) drug efflux pump.49-51 
 
 
 
Figure 1: Structures of some modified cyclic peptides in the cyanobactin 
family showing heterocycles, epimerized stereocentres and prenylated 
residues in trunkamide A.   
 
Patellamides are the most studied members of the cyanobactins. 
They were originally isolated from extracts of the Indo-Pacific 
ascidian Lissoclinum patella, but shown later to be produced by its 
cyanobacterial symbiont Prochloron sp..52,53 Genomic studies of 
Prochloron sp. delineated the gene cluster for the biosynthesis that 
directs the production of the patellamides.54-59 Their biosynthesis 
occurs via the production of a ribosomally encoded precursor 
peptide, in which a core peptide sequence is modified by a series 
of processing enzymes.52,60-64 We recently used these enzymes in 
vitro to generate natural and non-natural cyanobactins in milligram 
quantities.61 Accurate quantification of the reaction products is 
essential to calculate yields before and after purification and for 
their downstream biological screening but is challenging due to the 
lack of authentic standards.  
To overcome this, we herein report two quantification methods, 
the first relies on the quantification of the sulfur content in the 
products to estimate the concentration of these new heterocycle 
containing cyclic peptides in solutions, by coupling molecular 
electrospray mass spectrometry (ESIMS) and elemental 
inductively coupled plasma mass spectrometry (ICPMS) to a high 
pressure liquid chromatograph (HPLC) in parallel.65 Using this 
approach we quantified sulfur containing peptides obtained after 
extraction and purification of these compounds from 
chemoenzymatic reaction mixtures and identified the most 
efficient extraction and purification strategy. While the second 
method describes an alternative quantification method using NMR 
and an ERETIC (electronic reference to access in vivo 
concentrations) reference for the quantification of non- sulfur 
containing cyclic peptides. ERETIC qNMR enabled us to obtain 
the concentration and identity of these new compounds 
simultaneously.  
 
2. Results and Discussion 
2.1. Verification of sulfur quantification by HPLC 
Two sulfur containing compounds 1 and 2 (Table 1, SI Scheme 1) 
were used as calibration standards. The accuracy of the method 
was verified using, a known drug molecule containing sulfur; 
methylthioninium chloride 3, commercially available sulfate 
standard solution and three certified reference materials (CRMs): 
RM8415 (whole egg powder); BCR-062 (olive leaves) and 
seronorm (trace elements in urine blank) whose total sulfur 
contents are known were analysed. The detection limits for sulfur 
by HPLC ranged from 1.00 to 2.03 x 10-4 mg/mL using either 
compound 1 or 2 as standard, with a correlation coefficient > 0.99. 
There was no statistically significant difference in the results using 
either compound 1 or 2 for quantification of sulfur in the samples. 
Recovery of sulfur in the three certified reference materials was 
101 ± 8 % and compound 3 was 78 ± 2 % (Table 2). The sulfur 
content of the HPLC calibration standards (1 and 2) was within the 
calculated range (± 3 %) allowing their use as standards in HPLC-
ICPMS/ESMS.  
 
Table 1: Names of compounds studied with their molecular 
formula and molecular masses in g/mol.  
NAME/SEQUENCE MOLECULAR 
FORMULA 
MASS 
(g/mol) 
Cysteine (1) C3H7NO2S 121.16 
N-acetyl cysteine (2) C5H9NO3S 163.19 
Methylthioninium chloride (3) C16H18ClN3S 319.85 
Patellamide D (4) C38H48N8O6S2 776.97 
Ascidiacyamide (5) C36H52N8O6S2 756.98 
Cyclo[IFTV(ThH)I(ThH)V(ThH)] (6) a C44H65N9O7S3 928.24 
Cyclo[ITM(ThH)ITM(ThH)] (7) a C36H60N8O8S4 861.17 
Cyclo[I(MeOxH)V(ThH)I(MeOxH)V(ThH)] 
(8) b 
C36H56N8O6S2 761.01 
Cyclo[ITA(ThH)ITF(ThH)] (9) a C38H56N8O8S2 817.03 
Cyclo[GITA(ThH)I(ThH)V(ThH)] (10) a C36H56N8O7S3 809.07 
Anthranilic acid (11) C7H7NO2 137.14 
Cyclo[VGAGIGWP] (12) c C36H51N9O8 737.86 
Cyclo[I(MeOxH)A(Thz)I(MeOxH)A(Thz)] 
(13) d 
C32H44N8O6S2 700.87 
Cyclo[IPA(Thz)I(MeOxH)F(Thz)] (14) d C39H50N8O6S2 790.32 
Cyclo[IPA(Thz)IPFThz)] (15) e C40H52N8O6S2 805.02 
Cyclo[ITA(Thz)IPF(Thz)] (16) e C39H52N8O7S2 809.01 
Modified cyclic peptides prepared from the corresponding linear peptides by 
processing with: aTruD heterocyclase, which converts Cys to thiazoline, followed by 
PatGmac; bPatD heterocyclase, which converts Cys, Ser, Thr to thiazoline, oxazoline and 
methyl oxaxoline respectively, followed by PatGmac, cMacrocylicization by PatGmac, 
dMicD heterocyclase, which converts Cys to thiazoline, Thr to methyl oxaxoline, followed 
by PatGmac, followed ArtGox and eLynD heterocyclase, which converts Cys to thiazoline, 
followed by PatGmac and ArtGox. 
Quantification of compound 3 gave a recovery of 75 ± 3 % 
(Table 2) of the theoretical value which is similar to the value 
achieved during total sulfur determination. This indicates that 
there was no loss of compound 3 on the column, that the standards 
used for quantification and the methods used are of sufficient 
accuracy. 
 
Table 2: Sulfur quantification results for the concentration of 
compound 3 and certified reference materials in mg 
compound/g solution. 
Sample 
(n=3) 
Theoretical  
mg compound/g 
Found  
mg compound/g 
3 1.41  1.34 ± 0.0439 
Total S in CRM's Certified Value mg/kg  
RM8451  5120 ± 500  4762 ± 54 
BCR-062  1600 (indicative 
value)  
1588 ± 32 
Seronorm urine   545 (513-577)  617 ± 123 
 
2.2. Naturally occurring cyclic peptides 
    As a proof of concept, purified natural products 4 and 5 were 
obtained from an Australian collection of the seasquirt 
Lissoclinum patella. These natural products were subjected to 
HPLC-ICPMS/ESMS. The observed peaks for each sample in 
both positive mode ES-MS and ICP-MS were at the same retention 
time (tR) (Figure 2). Quantification of compound 4 [777 (M+H)+] 
with tR of 23.2 min (Figure 2A) revealed that the total solid mass 
of compound 4 in the analysed sample was between 29.0 to 30.8 
% (Table 3). Compound 5 [757 (M+H)+]  with a tR of 24.3 min 
(Figure 2B) had between 84 and 89 % total solid in the analysed 
sample (Table 3), using the developed method for quantification 
with compounds 1 or 2 as standard.  
 
 
Figure 2: Separation of compound 4 and 5 containing solids and detection 
by ICPMS (red) and ESMS (blue), A) ICP-MS and extracted ion count (EIC) 
chromatograms of compound 4, B) ICP-MS and extracted ion count (EIC) 
chromatograms of compound 5. 
 
2.3. Biosynthetic peptides 
For HPLC-ICP-MS quantification, interferences were 
efficiently removed in the ICP-MS/MS with selection of dual m/z, 
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for sulfur quantification, by measuring S, m/z 32 and 34 were 
obtained as 32S16O+ and 34S16O+ preventing m/z 48 and 50 
interferences66. Cyclic peptides 6-10 were extracted from 
chemoenzymatic reaction mixtures using SPE and subsequently 
identified and quantified by HPLC-ICPMS/ESMS. Solutions of 
samples 3 to 10 for species quantification were injected in 
triplicate and results are given as mean ± SD except 8 and 9 (Table 
3). These samples showed the presence of the respective peptides 
at different tRs (Figure S1- S5i in Supporting Information) the 
sulfur peak areas at each tRs for each compound was used for their 
individual quantification. Quantification results of the samples 
revealed that compound 6 and 7 contained 39.5 % and 3.60 %, of 
the desired peptides respectively, while compound 8 contributed 
75.8 % to the analysed fraction, 5.0 % of compound 9 was present 
in the analysed sample and compound 10 contained 11.5 % of the 
peptide. RP-SPE method is useful for desalting and fractionation 
for compound before quantification, however data show that the 
estimated weight of samples was influenced by significant 
amounts of non-targeted compounds (data not shown) may be the 
reason for observed low concentrations for 6, 7, 9 and 10 after 
quantification, compared to the data obtained for 8, which was 
purified by HPLC. Recent studies by Møller et al67 for peptides in 
human plasma and Hermann et al.68 report for S-containing 
proteins shows the applicability of this method for accurate 
quantification of peptides. 
 
Table 3: Theoretical concentration of samples, average 
amount of compounds recovered after quantification by sulfur 
for compounds 4, 5, 6, 7, 8, 9 and 10 in µg/m, % compound 
recovery and purification methods. 
Sample Theoretical 
concentration 
(g 
compound/mL) 
Average 
compound 
recovery g 
compound/mL 
 
% 
compound 
recovery 
Purification 
method   
4a 97.80 28.40 0.725 29.70 HPLC 
4b 49.41 15.22 0.4650 30.80 HPLC 
5a 135.6 115.0  1.991 84.80 HPLC 
5b 41.70 37.13 1.112 89.00 HPLC 
6 899.4 355.0 3.098 39.50 SPE 
7 1400 50.33 4.752 3.60 SPE 
8 250.0 189.4 75.80 HPLC 
9 987.5 49.78 5.00 SPE 
10 1228 141.6 17.36 11.50 SPE 
a and b are different concentrations for each sample. 
 
2.4. Comparison of Extraction Methods 
Quantification of samples obtained using various extraction 
methods for compound 10 revealed that reverse phase solid phase 
extraction RP-SPE gave optimum compound recovery and purity 
(Table 4). The protein concentrator and crude sample showed 
more peaks at retention times before 5 min due to high 
concentration of inorganic sulfate (Figure S7).  This confirms the 
need for SPE in sample preparation of target compounds/ 
analytes,69,70 as it increases the recovery of the compounds by 
removing the salts from the reaction buffer by selective 
isolation/fractionation of the cyclic peptides from the reaction 
mixture. This is consistent with work carried out by Loroch et al. 
using RP-SPE for phosphopeptide fractionation71. The protein 
concentrator fractions also showed the presence of other non-
identified sulfur containing compounds, which eluted through the 
filter with the compound of interest as the filter does not 
selectively isolate the apolar cyclic peptides from the more polar 
linear peptides, in contrast to the SPE process, hence reducing the 
percentage purity of the extract. We also observed that the 70 Å 
SPE cartridge with a smaller pore size had a higher sample yield 
for our compounds in comparison to the 125 Å SPE cartridge.  
Table 4: Sample total dry weight, percentage purity and yield 
for each extraction method applied to compound 10 based on 
enrichment factor. 
Sample Sample 
total dry 
weight 
(mg) 
Ratio of 
compound/total 
solid 
% purity % 
compound 
recovery 
 
Crude 0.30 0.13 0.046±0.0072  
SPE_125Å 0.031 0.082 8.5±2.5 10 
SPE_70Å 0.059 0.099 14 ±3.2 19 
Supernatant 0.054 0.12 1.8±0.21 18 
Filtrate 0.18 0.18 0.28±0.15 61 
 
 
2.5. Verification of quantification by NMR 
Compound 11 was used as an external reference material for 
calculating the ERETIC concentration of cyclic peptides (Table 5). 
Validation of this method for our system was achieved by 
comparing the calculated ERETIC concentration to that obtained 
by UV-absorbance at 280nm. A 500µL DMSO-d6 solution of 12 
gave a theoretical concentration of 13 mM, equating to 5.1 mg of 
12 by UV. A qNMR spectrum of 11 was recorded and one of the 
benzyl-hydrogen peaks was integrated, set to 10 mM and used for 
the ERETIC reference. Compound 12 was diluted to 600µL and 
qNMR spectrum was recorded. The distinct indole nitrogen peak 
was integrated, and its value compared to that of the ERETIC 
reference which gave a concentration of 13 mM, which 
corresponded to a total of 5.1 mg of 12 (see Figure S7 for 1H NMR 
spectra). The total solid amount of 12 determined via UV 
absorbance and ERETIC quantification were with 5.06 and 5.08 
mg respectively similar, thus showing that qNMR can be used to 
accurately determine the total solid in a purified cyclic peptide. 
 
2.6. Peptide Quantification by NMR 
Quantification of the naturally occurring peptides 4 and 5 
(Table 5 and Figure S8 and S10) showed that compound 4 was       
99 % pure and compound 5 was 75 % pure. The synthetic peptides 
subsequently quantified (Table 5 and Figure S11 to S14) showed 
that compound 13 contained of 21 % of analysed sample, 
compound 14 contained 34 % of the peptide while 15 and 16 
contained 19 % and 33 % of the total solid of the analysed samples 
respectively. Given the high purity of compounds 13-16 we 
suggest that the low percentage of compound per total mass of 
powder can be attributed to significant retention of water during 
the freeze-drying process, which is supported by a large water peak 
(~ 3.3 ppm) in the NMR spectra (Figure S11-14) similar to the 
finding of Frank et al.72 analytical data presented shows that the 
actual quantity compounds were under estimated in the 
preparation of the stock solution.   
 
Table 5: Weighed mass sample, concentration of compound 
and % compound obtained after qNMR quantification with 
their respective unit. 
Sample Weighed mass 
of sample (mg) 
Experimental 
mass of compound 
(mg) 
% 
compound 
recovery  
4 5.70 5.67 99 
5 8.10 6.05 75 
13 1.50 0.31 21 
14 4.97 1.69 34 
15 1.60 0.30 19 
16 5.40 0.54 33 
 
3. Conclusion 
The samples batch containing 4 and 5 for the respective ICP-
MS and qNMR quantification were different.  A low compound 
recovery for 4 in the ICPMS quantification compared to the NMR 
method was attributed to the presence of other unidentified 
compound(s) which added to the weight of the purified compound 
used for analysis; assuming that ionization efficiency was equal, 
on calculation of the extracted ion peak area with the m/z for 4 used 
for each quantification method, the ICPMS sample had only 48 % 
while the NMR sample had 87 % of the compound mass. This may 
be the reason for the difference in quantification observed.  
Accurate quantification of natural and non-natural modified cyclic 
peptides at various stages of purification by HPLC-ICPMS/ESMS 
and 1H qNMR spectroscopic without the use of authentic standards 
is possible using these methods. Whereas the ICPMS method 
would be suitable for very small sample sizes with low purity and 
compounds containing a target element, the NMR method requires 
larger sample size and higher purity. Our data shows that these 
quantification methods can be applied to new compounds without 
authentic standards as they are not species specific but rely on 
elemental constitution of each compound. Application of these 
methods is possible for non-cyclic peptides as we were able to 
identify other organic and inorganic sulfur species using HPLC-
ICPMS/ESMS. These methods also eliminate the drawbacks 
associated with quantification by only HPLC, UV or ESMS and 
polyatomic spectral interference associated with ICPMS sulfur 
quantification. Data obtained also show that sulfur quantification 
can be used to measure the purity of peptides and product yield 
using different extraction methods accurately from microgram to 
milligram quantity. ERETIC based proton qNMR can be used to 
quantify peptides in the presence or absence of heteroatoms.  
 
4. Experimental  
4.1. Materials / methods 
4 .1 .1 .  Sample  
 
Samples used for this work, listed in Table 1 include azole 
containing cyclic peptides isolated from Lissoclinum patella 
sourced from Davies Reef (the Great Barrier Reef), Australia, from 
a collection made in 2006, and analogues synthesised using 
recombinant biosynthetic enzymes using the method previously 
reported in Houssen et al.61  
 
4.1 .2 .  Reagen ts  and chemicals  
 
Milli-Q water (18 MΩcm, Millipore, Germany) was used 
throughout the experiments. HPLC-solvents of highest purity 
available (methanol, acetonitrile and trifluoroacetic acid) were 
obtained from Sigma Aldrich (UK), whereas formic acid (>95 % 
reagent grade) was obtained from Fluka, UK. Nitric acid (69 %, 
p.a.) and hydrogen peroxide (30 %, trace select) were obtained 
from Fisher (UK) and DMSO-d6 (99.8 % purity manufactured by 
Cambridge Isotope Laboratories, USA). Cysteine 1 and N-
Acetylcysteine 2 used as sulfur standards were obtained from 
Sigma (UK) and anthranilic acid 11 used as ERETIC standard was 
>99.5 % purity from Sigma-Aldrich, UK. Sulfur standard (1g/L) 
for total sulfur determination, rhodium and gallium (1g/L) were 
obtained from High-Purity Standards (USA). Certified reference 
materials for total sulfur determination were RM8415 (Whole egg 
powder, NIST, USA), BCR-062 (olive leaves, IRMM Geel) and 
Seronorm Trace elements in urine blank (Sero, Norway) and the 
in-house material methylthioninium chloride 3.  
 
4.1 .3 .  Standards  for  ICPMS  
 
Standards for total sulfur determination were prepared in 2 % 
(v/v) nitric acid. Sulfur standards 1 and 2 for HPLC were prepared 
freshly each day by dissolution in water with a concentration range 
between 5 and 100 mg S/kg. 
 
4.1 .4 .  Microwave d iges t ion  for  to ta l  S   
 
For total sulfur determination in RM8415 and BCR-062 both 
materials were digested using an open microwave system 
(MARS5, CEM, USA) with 2 mL nitric acid and 1 mL hydrogen 
peroxide for 30 min at 95 oC. After cooling the samples were 
diluted with water to 2 % (v/v) nitric acid. Seronorm urine and 
compound 3 (dissolved in water) were diluted using 2 % (v/v) 
nitric acid before measurement. The HPLC standards were also 
acidified with nitric acid (final concentration 2 % v/v) for 
verification of sulphur concentration. 
 
4.1 .5 .  Sol id  Phase Extract ion  (SPE)  
 
Two types of SPE cartridges with silica as the sorbent were 
used to extract the peptides from protein mixtures using a vacuum 
extraction manifold (Phenomenex Strata 1 g C8, 55 µm 70 Å and 
Waters Sep – Pak 1 g C8, 37 -55 µm 125 Å). Each cartridge was 
conditioned with 5 column volumes (CV) of methanol and 5 CV 
of water after which the sample was loaded, washed with equal 
volume of water and subsequently eluted with 10 CV of 50: 50 v/v 
water: methanol, 10 CV of 100 % methanol, 10 CV of 100 % 
acetonitrile and finally with 10 CV of 0.05 % trifluoroacetic acid 
in acetonitrile. The methanol and acetonitrile fractions were 
combined and concentrated under a stream of nitrogen. Residual 
dry sample was then weighed and reconstituted with methanol 
before use. Phenomenex Strata cartridges were used for 
extractions for all the samples studied while Waters Sep – Pak was 
used only for comparison of extraction method for compound 10.   
 
4.1 .6 .  Extract ion  Methods  
 
An aliquot of compound 10 enzymatic reaction mixture was 
divided into 12 vials containing 3.2 mL each, to allow triplicate 
measurements of each sample treatment method. The first set of 
three sample aliquots were extracted using Phenomenex strata 1 g; 
70 Å C8 SPE, the methanol and acetonitrile eluates were then 
combined, concentrated, weighed and reconstituted in methanol 
for analysis, using the same treatment, the next set of samples was 
extracted using Waters 1 g; 125 Å C8 SPE column. The third set 
sample aliquots were transferred into 30 mL protein filters (protein 
concentrator MWCO 10,000 from GE Healthcare) and centrifuged 
at 2000 revolutions per minute (rpm) at 4 oC for 40 mins, the 
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resulting filtrate was transferred into pre-weighed glass vials and 
the supernatants were transferred into 2 mL protein filters, and 
centrifuged for 30 mins at 2000 rpm the resulting filtrate was 
transferred into the initial filtrate, frozen and then freeze dried 
before re-weighing. The samples were then dissolved in Milli-Q 
water for analysis, the supernatants obtained after filtration using 
the 2 mL protein filter was transferred into a separate pre-weighed 
glass vials, frozen and then freeze dried before reweighing. This 
was then reconstituted in Milli-Q water. The last set of 3.2 mL 
sample aliquot crude sample was put in pre-weighed vials, frozen 
and freeze dried; sample weight was obtained before dissolving in 
Milli-Q water for analysis.  
 
4.1 .7 .  1H NMR Quant i f ica t ion  
 
Pure (95 %) 12 (5.6 mg) of was dissolved in 500 μL DMSO-
d6. The concentration of 12 in solution was determined first by 
A280 using a theoretical extinction coefficient of 5500 M
-1 cm-1 as 
calculated by ExPASy ProtParam. A280 measurements were 
performed on a NanoDrop ND-1000 spectrophotometer, which 
returned a concentration of 13 mM, equating to 5.1 mg of product. 
The solution was diluted to 600 μL and transferred to an NMR tube 
for qNMR and the spectrum recorded. A 1M solution of 11 was 
prepared in DMSO and subsequently diluted to 10 mM using 
DMSO-d6 before obtaining the qNMR spectrum. From this 
spectrum one of the well-defined and isolated benzyl-hydrogen 
peaks was integrated and set to 10 mM as an ERETIC reference. 
The concentration of 12 was calculated by integrating the well-
defined and isolated indole nitrogen peak and comparing the value 
with that of the ERETIC reference. Synthetic peptides 13-16 were 
quantified using the same procedure, data were analysed using 
TopSpin software (Bruker). 
The dry mass of 4 and 5 weighed and dissolved in 800 µL of 
DMSO-d6, 99 mM stock solution of 11 in DMSO-d6 was prepared 
from which 50 mM and 20 mM were made up. Proton NMR was 
acquired for the standards and samples sequentially on the same 
day using 5 mm tubes. Data was analysed using qNMR on 
MestReNova software for compound quantification. 
 
4.2. Instrumentation/Methods 
4 .2 .1 .  ICPMS (to ta l  su lphur  de termina t ion )  
An Agilent 8800 (Agilent Technologies, USA) was used for 
total sulfur determination. The instrument was used in MS/MS-
mode using oxygen as reaction gas. The general instrument 
parameters were optimized for robust plasma conditions using Ni-
cones. Sulfur was measured in mass-shift mode on m/z 49 (33S-> 
33S16O) and m/z 50 (34S -> 34S16O). Gallium (10µg/kg) was used as 
internal standard. 
 
4.2 .2 .  Prepara t ive HPLC Separat ion  
 
Reverse phase liquid chromatographic separation was used for 
sample separation using an Agilent 1260 infinity HPLC system; 
each sample separation gradient was developed depending on the 
best separation chromatogram observed using a UV detector.  
Chromatographic methods are as shown in Table 6, methods A and 
B were used for the purification of Lissoclinum patella extract to 
obtain 4 and 5, while methods C and D were analytical methods 
used for HPLC-ICPMS/ESMS.  
 
Table 6: LC separation gradient for the purification of 
compound 7 and 8 (method A and B) and methods C and D 
used for quantification. 
Instrument 
Parameter 
Method A 
preparative 
Method B 
preparative 
Method C 
Analytical 
Method D 
Analytical 
Column Sunfire C18 
10 µm 10 x 
250 mm D 
YMC-Pack 
pro C4, 3 
µm 12 nm, 
150 x 4.6 
mm D 
Agilent 
XBD- 
Eclipse C18, 
4.6 x 150 
mm D 
Poresize 5 
µm 
YMC-Pack 
Pro C4 150 
x4.6 mmD, 
S-3 µm 
 
Flowrate 1.5 mL/min 1.0 mL/min 0.9 mL/min 
 
0.9 mL/min 
Injection  
Volume 
 
200 L 100 L 20 L 20 L 
 
Column 
temperature 
30 oC 30 oC 35 oC 
 
35 oC 
 
Solvent A milliQ water milliQ water 0.1 % (v/v) 
Formic acid 
in water 
0.1 %  (v/v) 
Formic acid 
in water 
Solvent B 
 
Acetonitrile Acetonitrile 0.1 %  (v/v) 
Formic acid 
in Methanol 
0.1 % (v/v) 
Formic acid 
in Methanol 
Gradient 0- 20 min:   
0 – 100 % B 
20 – 32 min 
100 %  B 
 
0- 25 min:   
0 – 100 % B  
20 – 32 min 
100 %  B 
 
0 -25 min:   
0 – 100 % B 
25 – 35 min 
100 %  B 
0 – 20 min:  
10 – 100 % 
B 
20 - 25 min 
100 %  B 
 
 
 
4.2 .3 .  HPLC- ICPMS /  ESMS  
 
An Agilent 1100 HPLC system consisting of cooled 
autosampler, quaternary pump and column thermostat was used 
for the separation of the samples. The autosampler was cooled to 
4 oC, whereas the column was held at 35 oC. A sample volume of 
20 µL was used throughout. The columns and separation 
conditions used are summarized in Table 6 methods C and D. The 
column effluent was split 1:4 using a QuickSplit Post-Column 
Flow splitter (ASI, USA), with 1 part of the effluent infused into 
the ICPMS and 3 parts into the ES-MS. 
The ICPMS used was an 8800 Agilent system (Agilent 
Technologies, USA). The instrument was used in organic mode 
including Pt-cones, small ID torch and PFA-micronebulizer. 
Further instrument parameters are given in Table 7; the instrument 
was optimized daily for highest sensitivity under robust plasma 
conditions. Sulfur was determined using oxygen in the reaction 
cell in MS/MS mode using the mass-shifts of m/z 48 (32S-> 32S16O) 
and m/z 50 (34S34-> 34S16O). Rhodium (10µg/L) in 1 % nitric acid 
was used as continuous internal standard. To correct for intensity 
shifts due to the methanol gradient a blank run using a continuous 
internal standard containing sulfur and rhodium as described in 
Amayo et al65 was used for correction. 
An LTQ-Orbitrap Discovery from Thermo Scientific, UK was 
the ESMS system used for molecular identification. The splitter 
outlet (3 parts) was directly connected to the ES-inlet. The 
instrument was optimized daily for highest sensitivity and mass 
accuracy in positive mode. Further instrument parameters can be 
found in Table 7. 
 
Table 7: Instrumentation parameter for ICPMS and ESMS 
optimized for peptide quantification 
Instruments 
Parameter 
Value 
 
ICP-MS 
Mode  
 
HF 
Nebulizer- type 
Nebulizer gas 
Optional gas 
Plasma gas 
Coolant gas 
Reaction cell gas 
Reaction cell gas flow 
 
ESI - MS:  
 
Mode 
Resolution  
MSMS mode 
Ionspray voltage 
 
Agilent 8800 
Organic (Pt- cones, organic  
 torch, PFA- micronebulizer)  
1600W 
Microflow  
0.91 L/min 
6 % oxygen (80:20 Ar:O2) 
0.98 Lmin 
15.5 L/min 
O2  
0.3 mL/min 
 
LTQ Orbitrap Discovery 
(Thermo Scientific) 
Positive 
 30,000 
automatic  
4.5 KV 
 
 
4.2 .4 .  NMR  
 
NMR experiments were performed at 25 °C for 4 and 5 in a 
Bruker Ascend 400MHz NMR machine with a Z116098_0444 
(PA BBO 400S1 BBF-H-D-05 Z SP) probe while Bruker DRX500 
spectrometer equipped with a 5 mm TXIz probe was used for 13-
16. Data acquisition for all compounds was done at 64 scans, 10.00 
compensate, 90o pulse and 30 sec Delay.   
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